Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Adorini

Showing results (1-10 of 204) with videos related to

Pageof 21
Sort By:
Nature Genetics|February 15, 2001
Interleukin 12 and autoimmune diabetesL Adorini
Journal of Autoimmunity|April 1, 1992
Inhibition of T cell activation by MHC blockade: a possible strategy for immunointervention in autoimmune diseasesL Adorini
Clinical and Experimental Immunology|April 18, 2003
Cytokine-based immunointervention in the treatment of autoimmune diseasesL Adorini
Journal of Chemotherapy (Florence, Italy)|July 14, 2001
Selective immunointervention in autoimmune diseases: lessons from multiple sclerosisL Adorini
Clinical and Experimental Rheumatology|March 1, 1993
Selective inhibition of T cell responses by protein and peptide-based immunotherapyL Adorini
Transplantation Proceedings|August 1, 1992
Selective suppression of T-cell activation by administration of MHC class II-binding peptidesL Adorini
Clinical Immunology and Immunopathology|June 1, 1990
Antigen presentation and self-nonself discriminationL Adorini
The Year in Immunology|January 1, 1989
The presentation of antigen by MHC class II moleculesL Adorini
Idrugs : the Investigational Drugs Journal|August 16, 2005
New trends in clinical and experimental immunosuppression--fourth international conference. 17-20 February 2000, Geneva, SwitzerlandL Adorini
Cellular and Molecular Life Sciences : CMLS|October 20, 1999
Interleukin-12, a key cytokine in Th1-mediated autoimmune diseasesL Adorini
Pageof 21

Showing results (1-10 of 204) with videos related to

Sort By:
Pageof 21
Nature Genetics|February 15, 2001
Interleukin 12 and autoimmune diabetesL Adorini
Journal of Autoimmunity|April 1, 1992
Inhibition of T cell activation by MHC blockade: a possible strategy for immunointervention in autoimmune diseasesL Adorini
Clinical and Experimental Immunology|April 18, 2003
Cytokine-based immunointervention in the treatment of autoimmune diseasesL Adorini
Journal of Chemotherapy (Florence, Italy)|July 14, 2001
Selective immunointervention in autoimmune diseases: lessons from multiple sclerosisL Adorini
Clinical and Experimental Rheumatology|March 1, 1993
Selective inhibition of T cell responses by protein and peptide-based immunotherapyL Adorini
Transplantation Proceedings|August 1, 1992
Selective suppression of T-cell activation by administration of MHC class II-binding peptidesL Adorini
Clinical Immunology and Immunopathology|June 1, 1990
Antigen presentation and self-nonself discriminationL Adorini
The Year in Immunology|January 1, 1989
The presentation of antigen by MHC class II moleculesL Adorini
Idrugs : the Investigational Drugs Journal|August 16, 2005
New trends in clinical and experimental immunosuppression--fourth international conference. 17-20 February 2000, Geneva, SwitzerlandL Adorini
Cellular and Molecular Life Sciences : CMLS|October 20, 1999
Interleukin-12, a key cytokine in Th1-mediated autoimmune diseasesL Adorini
Pageof 21